Ophthalmology Education and CME

Select a Specialty

MIGS and Cataract Surgery
CME

MIGS and Cataract Surgery

This activity is supported by educational grants from Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

Expiration Date: 4/2/2020
Credit Type(s): CME | Credit: 0.25

This educational video will discuss the benefits and complications of minimally invasive glaucoma surgery….

go to activity»
Rapid Response From Retina World Congress – Transitioning Treatment in Diabetic Retinopathy
CME

Rapid Response From Retina World Congress – Transitioning Treatment in Diabetic Retinopathy

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Expiration Date: 3/30/2020
Credit Type(s): CME | Credit: 0.75

Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, offering delayed or arrested disease progression and the…

go to activity»
ROCK-solid Inhibition in Glaucoma Therapy
CME

ROCK-solid Inhibition in Glaucoma Therapy

This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.

Expiration Date: 3/17/2020
Credit Type(s): CME | Credit: 0.75

The medical management of glaucoma is primarily focused on lessening intraocular pressure (IOP) by reducing aqueous humor formation or improving the drainage of aqueous…

go to activity»
Retina 2019: What’s New in Tie2?
CME

Retina 2019: What’s New in Tie2?

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 2/20/2020
Credit Type(s): CME | Credit: 0.75

The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapy into management algorithms for the treatment of patients with neovascular retinal…

go to activity»
Progressive Pathways in Treating Neovascular Retinal Disease: Exploring Tie2
CME

Progressive Pathways in Treating Neovascular Retinal Disease: Exploring Tie2

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 1/14/2020
Credit Type(s): CME | Credit: 1.25

The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapy into management algorithms for the treatment of patients with neovascular retinal…

go to activity»
Visualizing the Latest In DME Management: Implementing Novel Treatment Strategies to Improve Patient Outcomes
CMECE

Visualizing the Latest In DME Management: Implementing Novel Treatment Strategies to Improve Patient Outcomes

Supported by an educational grant from Allergan Inc.

Expiration Date: 12/17/2019
Credit Type(s): CME / Participation | Credit: 0.75

Despite the critical role of vascular endothelial growth factor (VEGF) inhibitors in managing patients with diabetic macular edema (DME), up to half of patients fail to…

go to activity»
Neuroprotection in Glaucoma
CME

Neuroprotection in Glaucoma

This activity is supported by educational grants from Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

Expiration Date: 4/2/2020
Credit Type(s): CME | Credit: 0.25

This educational activity will review the latest developments and concepts regarding neuroprotection in patients with glaucoma….

go to activity»
1,800 Seconds™ in Advances in the Management of Age-Related Macular Degeneration
CME

1,800 Seconds™ in Advances in the Management of Age-Related Macular Degeneration

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation

Expiration Date: 3/31/2020
Credit Type(s): CME | Credit: 0.5

Age-related macular degeneration (AMD) is the leading cause of blind registration in industrialized countries, and the third leading cause of blindness internationally…

go to activity»
A Clearer Focus: Moving Forward to Improve the Management of Ocular Surface Disease.
CME

A Clearer Focus: Moving Forward to Improve the Management of Ocular Surface Disease

This activity is supported by an educational grant from Shire.

Expiration Date: 2/27/2020
Credit Type(s): CME | Credit: 0.75

Ocular surface disease (OSD) encompasses several disorders which include dry eye disease, blepharitis, meibomian gland dysfunction, ocular allergy, and conjunctivitis…

go to activity»
Long-term Management of Neovascular AMD: Meeting the Need for Improvement
CME

Long-term Management of Neovascular AMD: Meeting the Need for Improvement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Expiration Date: 2/13/2020
Credit Type(s): CME | Credit: 0.75

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment. As prevalence of AMD continues to increase, it is estimated…

go to activity»
Multidisciplinary Perspectives in Giant Cell Arteritis A Team Based Approach
CME

Multidisciplinary Perspectives in Giant Cell Arteritis: A Team-based Approach for Improved Quality of Care

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 12/1/2019
Credit Type(s): CME | Credit: 1.25

Giant cell arteritis (GCA) is the most common form of medium- and large-vessel vasculitis. If left untreated, patients with GCA are at increased risk for various short-…

go to activity»
Ocular Surface Diseases, Disorders, and Dysfunctions®, Volume 4, Number 3
COPECME

Ocular Surface Diseases, Disorders, and Dysfunctions®, Volume 4, Number 3

This activity is supported by an educational grant from Shire.

Expiration Date: 12/1/2019
Credit Type(s): CME / COPE | Credit: 1.25

Ocular surface disease (OSD) is a group of disorders commonly seen in ophthalmic practice, but it is challenging to differentially diagnose and is frequently…

go to activity»